Vandetanib Terminated Phase 2 Trials for Invasive Breast Cancer Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01934335Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer